

Matthew J Maurer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3289469/publications.pdf>

Version: 2024-02-01

278
papers

11,197
citations

41344
49
h-index

33894
99
g-index

278
all docs

278
docs citations

278
times ranked

14114
citing authors

#	ARTICLE	IF	CITATIONS
1	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. Blood Advances, 2022, 6, 1350-1360.	5.2	9
2	Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials. Blood Cancer Journal, 2022, 12, 1.	6.2	7
3	Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey. Blood Advances, 2022, 6, 2745-2756.	5.2	3
4	Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121009038.	3.9	6
5	Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. Lancet Haematology, 2022, 9, e289-e300.	4.6	24
6	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. Blood Cancer Journal, 2022, 12, 78.	6.2	1
7	Therapy for patients with POD24 follicular lymphoma: Treatment patterns and outcomes from the Lymphoma Epidemiology of Outcomes (LEO) Consortium.. Journal of Clinical Oncology, 2022, 40, 7573-7573.	1.6	0
8	Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. Blood Advances, 2022, 6, 5210-5221.	5.2	2
9	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia, 2021, 35, 522-533.	7.2	28
10	Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors. Leukemia and Lymphoma, 2021, 62, 247-251.	1.3	8
11	The association of health behaviors with quality of life in lymphoma survivors. Leukemia and Lymphoma, 2021, 62, 271-280.	1.3	6
12	Testicular ^{FDC}PET</sup>/^{CT} uptake threshold in aggressive lymphomas. American Journal of Hematology, 2021, 96, E81-E83.	4.1	3
13	Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer. Gynecologic Oncology, 2021, 160, 520-529.	1.4	10
14	JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis. Blood Cancer Journal, 2021, 11, 56.	6.2	3
15	The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma. Haematologica, 2021, 106, 2261-2264.	3.5	0
16	Relapsed/Refractory International Prognostic Index (R^RIPI</sup>): An international prognostic calculator for relapsed/refractory diffuse large B^{cell} lymphoma. American Journal of Hematology, 2021, 96, 599-605.	4.1	8
17	Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting. Scientific Reports, 2021, 11, 8076.	3.3	9
18	Reversing the restrictive trend in diffuse large B^{cell} lymphoma trial eligibility: it's time to open the gates!. British Journal of Haematology, 2021, 193, 697-698.	2.5	0

#	ARTICLE	IF	CITATIONS
19	Prognostic impact of depth of response in Waldenström macroglobulinemia patients treated with fixed duration chemoimmunotherapy.. Journal of Clinical Oncology, 2021, 39, 8049-8049.	1.6	1
20	Type of tissue biopsy and outcomes in diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2021, 39, e13569-e13569.	1.6	1
21	Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?. Journal of Clinical Oncology, 2021, 39, 1641-1649.	1.6	16
22	Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. American Journal of Hematology, 2021, 96, 979-988.	4.1	5
23	Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review. Blood Advances, 2021, 5, 2426-2437.	5.2	24
24	Body mass index and survival of patients with lymphoma. Leukemia and Lymphoma, 2021, 62, 2671-2678.	1.3	5
25	Surveillance imaging during first remission in follicular lymphoma does not impact overall survival. Cancer, 2021, 127, 3390-3402.	4.1	6
26	Aortic Stenosis Progression, Cardiac Damage, and Survival. JACC: Cardiovascular Imaging, 2021, 14, 1113-1126.	5.3	26
27	Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. Blood Cancer Journal, 2021, 11, 133.	6.2	4
28	Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria. HemaSphere, 2021, 5, e640.	2.7	7
29	Cardiac Scintigraphy and Screening for Transthyretin Cardiac Amyloidosis. Circulation, 2021, 144, 1005-1007.	1.6	8
30	Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. American Journal of Surgical Pathology, 2021, 45, 384-393.	3.7	10
31	Cardiovascular Diseases That Have Emerged From the Darkness. Journal of the American Heart Association, 2021, 10, e021095.	3.7	5
32	Follicular Lymphoma Tumor-Cell Transcriptional Programs Associate with Distinct Somatic Alterations and Tumor-Immune Microenvironments. Blood, 2021, 138, 1327-1327.	1.4	0
33	High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients. Blood, 2021, 138, 181-181.	1.4	14
34	Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥65 Years Receiving Bendamustine-Rituximab. Blood, 2021, 138, 3517-3517.	1.4	1
35	Vaccination History and Risk of Lymphoma and Its Major Subtypes. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0383.2021.	2.5	1
36	Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium. Blood, 2021, 138, 744-744.	1.4	15

#	ARTICLE	IF	CITATIONS
37	Mismatch-Repair Deficiency in Follicular Lymphoma Tumors Is Common and Associated with a Favorable Overall Survival. <i>Blood</i> , 2021, 138, 3523-3523.	1.4	0
38	CHFR and Paclitaxel Sensitivity of Ovarian Cancer. <i>Cancers</i> , 2021, 13, 6043.	3.7	0
39	Novel Salvage Regimens Lead to Better Response and Survival in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant. <i>Blood</i> , 2021, 138, 878-878.	1.4	3
40	The Impact of Trial Eligibility Criteria on Outcomes in a Nationwide Cohort of Newly Diagnosed DLBCL Patients Treated with R-CHOP. <i>Blood</i> , 2021, 138, 53-53.	1.4	1
41	Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era. <i>Blood</i> , 2021, 138, 2429-2429.	1.4	1
42	Event-Free and Overall Survival in over 6,000 Patients Treated with Frontline Immunochemotherapy for Follicular Lymphoma between 2002-2018: First Report from the International FLIPI24 Consortium. <i>Blood</i> , 2021, 138, 3527-3527.	1.4	1
43	Evaluation of Eligibility Criteria in First-Line Clinical Trials for Follicular Lymphoma: A MER/LEO Database Analysis. <i>Blood</i> , 2021, 138, 338-338.	1.4	0
44	Time to Refractory Status Defines Subsets of Primary Refractory Diffuse Large B-Cell Lymphoma with Distinct Outcomes. <i>Blood</i> , 2021, 138, 2524-2524.	1.4	1
45	PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts. <i>Blood</i> , 2021, 138, 2508-2508.	1.4	0
46	Integration of Tumor Transcriptomic, Genomic, and Immune Profiles Reveals Distinct Populations of Low-Grade B-Cell Lymphomas with Poor Outcome. <i>Blood</i> , 2021, 138, 808-808.	1.4	0
47	Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy. <i>Blood</i> , 2021, 138, 2527-2527.	1.4	3
48	Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2020, 71, 1221-1228.	5.8	22
49	Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. <i>Cancer</i> , 2020, 126, 894-907.	4.1	54
50	Compliance with cancer screening and influenza vaccination guidelines in non-Hodgkin lymphoma survivors. <i>Journal of Cancer Survivorship</i> , 2020, 14, 316-321.	2.9	5
51	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. <i>Blood Cancer Journal</i> , 2020, 10, 117.	6.2	18
52	Leveraging Gene Expression Subgroups to Classify DLBCL Patients and Enrich for Clinical Benefit to a Novel Agent. <i>Blood</i> , 2020, 135, 1008-1018.	1.4	12
53	Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: <scp>CALGB</scp>/Alliance 50403. <i>American Journal of Hematology</i> , 2020, 95, 583-593.	4.1	18
54	The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3397-3407.	7.0	45

#	ARTICLE	IF	CITATIONS
55	High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?. Blood Cancer Journal, 2020, 10, 5.	6.2	22
56	Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma. Oncologist, 2020, 25, 689-695.	3.7	7
57	Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. British Journal of Haematology, 2020, 189, 661-671.	2.5	12
58	Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. Blood, 2020, 136, 7-8.	1.4	2
59	Describing Treatment of Primary Mediastinal Large B Cell Lymphoma Using Rigorously Defined Molecular Classification: A Retrospective Analysis. Blood, 2020, 136, 35-36.	1.4	1
60	Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment. Blood, 2020, 136, 21-22.	1.4	0
61	Body Mass Index and Survival of Patients with Lymphoma. Blood, 2020, 136, 2-3.	1.4	0
62	Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era. Blood, 2020, 136, 36-37.	1.4	0
63	The Expression of Chromosome Region Maintenance Protein 1 (CRM1) in Large Cell Lymphoma. Blood, 2020, 136, 39-40.	1.4	0
64	Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 26-27.	1.4	1
65	Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas. Blood, 2020, 136, 15-16.	1.4	0
66	Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood Cancer Journal, 2019, 9, 59.	6.2	9
67	Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. Blood, 2019, 134, 1289-1297.	1.4	26
68	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer Journal, 2019, 9, 73.	6.2	37
69	53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. Gynecologic Oncology, 2019, 153, 127-134.	1.4	56
70	Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. Journal of Clinical Oncology, 2019, 37, 1819-1827.	1.6	44
71	Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma. British Journal of Haematology, 2019, 186, 820-828.	2.5	12
72	ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. Haematologica, 2019, 104, e562-e565.	3.5	38

#	ARTICLE	IF	CITATIONS
73	Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma. American Journal of Hematology, 2019, 94, 786-793.	4.1	15
74	Host genetic variation in tumor necrosis factor and nuclear factor- κ B pathways and overall survival in mantle cell lymphoma: A discovery and replication study. American Journal of Hematology, 2019, 94, E153-E155.	4.1	1
75	The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. American Journal of Hematology, 2019, 94, 658-666.	4.1	19
76	Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas. British Journal of Haematology, 2019, 186, e24-e27.	2.5	15
77	Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. Journal of Clinical Oncology, 2019, 37, 144-152.	1.6	142
78	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. Journal of Clinical Oncology, 2019, 37, 1790-1799.	1.6	266
79	POD24 in MZL: a means to an end or an end point in itself?. Blood, 2019, 134, 787-788.	1.4	4
80	Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A. PLoS ONE, 2019, 14, e0224564.	2.5	6
81	Pre-treatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy. Clinical Epidemiology, 2019, Volume 11, 987-996.	3.0	5
82	Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. British Journal of Haematology, 2019, 184, 524-535.	2.5	27
83	Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma. American Journal of Hematology, 2019, 94, E62-E64.	4.1	15
84	Reply to the letter to the editor "Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting" by van der Galiën et al.. Annals of Oncology, 2019, 30, 153.	1.2	0
85	Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC). Blood, 2019, 134, 400-400.	1.4	2
86	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. Blood, 2019, 134, 72-72.	1.4	2
87	Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium. Blood, 2019, 134, 763-763.	1.4	42
88	Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL). Blood, 2019, 134, 69-69.	1.4	9
89	Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma. Blood, 2019, 134, 2896-2896.	1.4	2
90	Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients. Blood, 2019, 134, 5215-5215.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 919-919.	1.4	0
92	Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse. <i>Blood</i> , 2019, 134, 923-923.	1.4	0
93	Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era. <i>Blood</i> , 2019, 134, 422-422.	1.4	0
94	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2018, 93, 57-68.	2.8	90
95	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. <i>Blood</i> , 2018, 132, 49-58.	1.4	130
96	Online Physician Reviews Do Not Reflect Patient Satisfaction Survey Responses. <i>Mayo Clinic Proceedings</i> , 2018, 93, 453-457.	3.0	37
97	Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. <i>Blood Cancer Journal</i> , 2018, 8, 26.	6.2	92
98	A susceptibility locus for classical Hodgkin lymphoma at 8q24 near <i>MYC</i> predicts patient outcome in two independent cohorts. <i>British Journal of Haematology</i> , 2018, 180, 286-290.	2.5	13
99	Variability of performance status assessment between patients with hematologic malignancies and their physicians. <i>Leukemia and Lymphoma</i> , 2018, 59, 695-701.	1.3	11
100	Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. <i>British Journal of Haematology</i> , 2018, 183, 149-152.	2.5	5
101	Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. <i>Haematologica</i> , 2018, 103, 297-303.	3.5	17
102	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1603-1610.	1.6	93
103	Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma. <i>Blood Cancer Journal</i> , 2018, 8, 110.	6.2	22
104	Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?. <i>Nutrition and Cancer</i> , 2018, 70, 1088-1090.	2.0	4
105	Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma. <i>Blood Cancer Journal</i> , 2018, 8, 97.	6.2	36
106	The association of physical activity before and after lymphoma diagnosis with survival outcomes. <i>American Journal of Hematology</i> , 2018, 93, 1543-1550.	4.1	16
107	Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1123-1132.	6.3	83
108	Human Pegivirus infection and lymphoma risk and prognosis: a North American study. <i>British Journal of Haematology</i> , 2018, 182, 644-653.	2.5	20

#	ARTICLE	IF	CITATIONS
109	History of autoimmune conditions and lymphoma prognosis. Blood Cancer Journal, 2018, 8, 73.	6.2	26
110	Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. Hematological Oncology, 2018, 36, 749-756.	1.7	13
111	Inferior survival in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements is not associated with <i>MYC/IG</i> gene rearrangements. Haematologica, 2018, 103, 1899-1907.	3.5	52
112	Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Annals of Oncology, 2018, 29, 1822-1827.	1.2	61
113	Association of Health Behaviors and Quality of Life in Lymphoma Survivors. Blood, 2018, 132, 4838-4838.	1.4	3
114	Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance). Blood, 2018, 132, 146-146.	1.4	6
115	Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era. Blood, 2018, 132, 454-454.	1.4	1
116	Clinical Characteristics and Outcomes of an Analysis of a Single Institution Experience of the 2017 World Health Organization (WHO) Classification of Post-Transplant Lymphoproliferative Disorders (PTLD). Blood, 2018, 132, 456-456.	1.4	4
117	Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL. Blood, 2018, 132, 4204-4204.	1.4	1
118	Prevalence and clinical correlates of vulnerable status using the Vulnerable Elders Survey 13 (VES-13) in newly diagnosed adult non-Hodgkin lymphoma (NHL) patients: A LEO cross-sectional analysis.. Journal of Clinical Oncology, 2018, 36, 10042-10042.	1.6	1
119	Clinical Significance of Testicular FDG-PET/CT Uptake in Aggressive Lymphomas. Blood, 2018, 132, 5401-5401.	1.4	1
120	Compliance with Age-Appropriate Screening for Malignancies and Influenza Vaccination in 3-Year Lymphoma Survivors. Blood, 2018, 132, 4791-4791.	1.4	0
121	Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder. Blood, 2018, 132, 2979-2979.	1.4	0
122	Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era. Blood, 2018, 132, 4140-4140.	1.4	0
123	<i>FCGR3A</i> / <i>2A</i> polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. Hematological Oncology, 2017, 35, 447-455.	1.7	9
124	Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes. Clinical Cancer Research, 2017, 23, 3794-3801.	7.0	103
125	Transthoracic Echocardiography versus Computed Tomography for Ascending Aortic Measurements in Patients with Bicuspid Aortic Valve. Journal of the American Society of Echocardiography, 2017, 30, 625-635.	2.8	31
126	Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma. American Journal of Hematology, 2017, 92, 752-758.	4.1	23

#	ARTICLE	IF	CITATIONS
127	Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes. <i>Clinical Cancer Research</i> , 2017, 23, 4077-4085.	7.0	80
128	Accuracy of 18-F FDC PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma – tissue remains the issue. <i>Leukemia and Lymphoma</i> , 2017, 58, 2342-2348.	1.3	10
129	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. <i>International Journal of Epidemiology</i> , 2017, 46, 1753-1754i.	1.9	57
130	Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab. <i>American Journal of Hematology</i> , 2017, 92, 1156-1162.	4.1	8
131	Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. <i>Blood</i> , 2017, 130, 1800-1808.	1.4	1,084
132	Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. <i>British Journal of Haematology</i> , 2017, 179, 50-60.	2.5	49
133	International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 4019-4026.	1.6	50
134	Changes in Quality of Life in Indolent Non-Hodgkin Lymphoma 3 Years after Diagnosis. <i>Blood</i> , 2017, 130, 917-917.	1.4	4
135	EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review. <i>Genes and Cancer</i> , 2017, 8, 589-599.	1.9	45
136	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 179-184.	4.1	41
137	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 1096-1101.	4.1	180
138	Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2016, 91, 776-781.	4.1	14
139	APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 4746-4755.	7.0	59
140	Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma. <i>Blood</i> , 2016, 128, 1104-1104.	1.4	1
141	Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas). <i>Blood</i> , 2016, 128, 155-155.	1.4	1
142	Prognostic Impact of Morphology, MYC Gene Partner and BCL2/BCL6 Translocation Status in "High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements". <i>Blood</i> , 2016, 128, 1750-1750.	1.4	2
143	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 1874-1874.	1.4	2
144	Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients. <i>Blood</i> , 2016, 128, 3027-3027.	1.4	5

#	ARTICLE	IF	CITATIONS
145	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. <i>Blood</i> , 2016, 128, 3034-3034.	1.4	5
146	Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 3035-3035.	1.4	5
147	Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL. <i>Blood</i> , 2016, 128, 5299-5299.	1.4	1
148	Outcomes of DLBCL Patients Entering Surveillance (without maintenance) after Immunochemotherapy in a Large Observational Study. <i>Blood</i> , 2016, 128, 3036-3036.	1.4	0
149	An International Assessment of Event-Free Survival at 24 Months (EFS24) and Subsequent Survival in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2016, 128, 920-920.	1.4	0
150	No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era. <i>Blood</i> , 2016, 128, 107-107.	1.4	0
151	Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 2935-2935.	1.4	0
152	The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF- κ B positive feedback loop in peripheral T-cell lymphoma. <i>Blood</i> , 2015, 125, 3118-3127.	1.4	68
153	Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. <i>Blood</i> , 2015, 125, 992-998.	1.4	47
154	Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. <i>American Journal of Hematology</i> , 2015, 90, 790-795.	4.1	221
155	Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic. <i>Gynecologic Oncology</i> , 2015, 137, 77-85.	1.4	15
156	Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2516-2522.	1.6	610
157	Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. <i>Gynecologic Oncology</i> , 2015, 137, 14-22.	1.4	79
158	Plasma immune analytes in patients with epithelial ovarian cancer. <i>Cytokine</i> , 2015, 73, 108-113.	3.2	31
159	Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1495-1504.	4.2	51
160	Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 3930-3937.	1.6	24
161	Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors. <i>Leukemia and Lymphoma</i> , 2015, 56, 434-439.	1.3	14
162	Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer. <i>Cancer Research</i> , 2015, 75, 22-30.	0.9	157

#	ARTICLE	IF	CITATIONS
163	Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy. Blood, 2015, 126, 2683-2683.	1.4	6
164	Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era. Blood, 2015, 126, 3992-3992.	1.4	1
165	QOL at 3 years after diagnosis in aggressive lymphoma survivors.. Journal of Clinical Oncology, 2015, 33, 9586-9586.	1.6	2
166	Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. Oncotarget, 2015, 6, 9488-9501.	1.8	42
167	Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers. Oncotarget, 2015, 6, 35737-35754.	1.8	23
168	Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 131-131.	1.4	0
169	Tissue Is the Issue: Accuracy of PET Imaging to Detect Bone Marrow Clearance in Patients with Peripheral T-Cell Lymphoma. Blood, 2015, 126, 3947-3947.	1.4	0
170	Lymphocyte-to-Monocyte Ratio at Diagnosis and Survival in De Novo Double/Triple Hit Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 3885-3885.	1.4	0
171	Event-Free Survival at 12 Months and Subsequent Overall Survival in Patients with Peripheral T-Cell Lymphoma. Blood, 2015, 126, 1501-1501.	1.4	0
172	Natural History of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era. Blood, 2015, 126, 1456-1456.	1.4	0
173	Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B-cell non-Hodgkin lymphoma. American Journal of Hematology, 2014, 89, 1116-1120.	4.1	16
174	Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein 10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma. American Journal of Hematology, 2014, 89, 417-422.	4.1	18
175	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-cell Lymphomas. American Journal of Surgical Pathology, 2014, 38, 768-775.	3.7	44
176	Large-Scale Evaluation of Common Variation in Regulatory T Cell-Related Genes and Ovarian Cancer Outcome. Cancer Immunology Research, 2014, 2, 332-340.	3.4	21
177	Tumorgrafts as <i>In Vivo</i> Surrogates for Women with Ovarian Cancer. Clinical Cancer Research, 2014, 20, 1288-1297.	7.0	168
178	Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. American Journal of Hematology, 2014, 89, 639-645.	4.1	26
179	Utility of Routine Post-Therapy Surveillance Imaging in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2014, 32, 3506-3512.	1.6	144
180	PatternCNV: a versatile tool for detecting copy number changes from exome sequencing data. Bioinformatics, 2014, 30, 2678-2680.	4.1	43

#	ARTICLE	IF	CITATIONS
181	Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 1066-1073.	1.6	304
182	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. <i>Blood</i> , 2014, 124, 1473-1480.	1.4	401
183	Elevated soluble IL-2R^{\pm} , IL-8 , and MIP-1^2 levels are associated with inferior outcome and are independent of MIP-1 score in patients with mantle cell lymphoma. <i>American Journal of Hematology</i> , 2014, 89, E223-7.	4.1	36
184	CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1475-1484.	4.2	28
185	Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. <i>Journal of Clinical Oncology</i> , 2013, 31, 3272-3278.	1.6	259
186	Survival Prediction Based on Inherited Gene Variation Analysis. <i>Methods in Molecular Biology</i> , 2013, 1049, 53-64.	0.9	1
187	The potential of serum light chains in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1857-1858.	1.3	1
188	Utility of Progranulin and Serum Leukocyte Protease Inhibitor as Diagnostic and Prognostic Biomarkers in Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1730-1735.	2.5	33
189	Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: Results from two independent cohorts. <i>Cytokine</i> , 2013, 64, 523-531.	3.2	16
190	FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status. <i>Leukemia and Lymphoma</i> , 2013, 54, 2571-2573.	1.3	7
191	APOBEC3B Upregulation and Genomic Mutation Patterns in Serous Ovarian Carcinoma. <i>Cancer Research</i> , 2013, 73, 7222-7231.	0.9	153
192	The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 290-297.	1.3	58
193	Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2013, 19, 6812-6819.	7.0	64
194	A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and ^{90}Y ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2013, 88, 589-593.	4.1	33
195	The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer. <i>PLoS ONE</i> , 2013, 8, e80063.	2.5	171
196	IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era. <i>Blood</i> , 2013, 122, 362-362.	1.4	2
197	In-Vivo Activation Of STAT3 In Angioimmunoblastic T Cell Lymphoma, PTCL Not Otherwise Specified, and ALK Negative Anaplastic Large Cell Lymphoma: Implications For Therapy. <i>Blood</i> , 2013, 122, 844-844.	1.4	5
198	Inherited Variants in Regulatory T Cell Genes and Outcome of Ovarian Cancer. <i>PLoS ONE</i> , 2013, 8, e53903.	2.5	20

#	ARTICLE	IF	CITATIONS
199	Whole-Exome Analysis Of DLBCL Tumors Reveals a Unique Genetic Signature Associated With Aggressive Disease. Blood, 2013, 122, 499-499.	1.4	2
200	Elevated Soluble IL-2Ra Levels Are Associated With Inferior Outcome and Is Independent Of MIPI Score in Patients With Mantle Cell Lymphoma. Blood, 2013, 122, 4256-4256.	1.4	0
201	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. Blood, 2013, 122, 76-76.	1.4	1
202	Variability Of Performance Status Assessment Between Patients With Hematologic Malignancies and Their Physicians. Blood, 2013, 122, 1703-1703.	1.4	0
203	Tumor Monocyte Cross Talk Promotes Chemotherapy Resistance In Lymphoma. Blood, 2013, 122, 1774-1774.	1.4	0
204	LIM domain only 2 protein expression, <i>LMO2</i> germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era. Leukemia and Lymphoma, 2012, 53, 1105-1112.	1.3	5
205	Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities. Modern Pathology, 2012, 25, 651-660.	5.5	66
206	Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. Blood, 2012, 120, 4400-4406.	1.4	53
207	Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: A clinic-based case-control study. Cytokine, 2012, 60, 882-889.	3.2	50
208	Inherited genetic variation and overall survival following follicular lymphoma. American Journal of Hematology, 2012, 87, 724-726.	4.1	13
209	Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. American Journal of Hematology, 2012, 87, 865-869.	4.1	37
210	Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma. American Journal of Hematology, 2012, 87, 880-885.	4.1	36
211	Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood, 2012, 119, 2844-2853.	1.4	149
212	Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population. Blood, 2012, 120, 1540-1540.	1.4	2
213	Rates and Outcomes of Follicular Lymphoma Transformation in the Rituximab Era: A Report From the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource. Blood, 2012, 120, 1546-1546.	1.4	1
214	EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV (âˆ“) Counterparts: Results From University of Iowa/Mayo Clinic SPORE. Blood, 2012, 120, 1604-1604.	1.4	1
215	Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Blood, 2012, 120, 684-684.	1.4	0
216	Expression of MYC but Not pSTAT3 Is an Adverse Prognostic Factor for Diffuse Large B Cell Lymphoma (DLBCL) Treated with Epratuzumab/R-CHOP. Blood, 2012, 120, 1575-1575.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-Cell Lymphomas: A North American PTCL Study Group Project. Blood, 2012, 120, 1545-1545.	1.4	6
218	Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. Blood, 2012, 120, 149-149.	1.4	0
219	Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. Blood, 2012, 120, 1563-1563.	1.4	0
220	Host Genetics and Risk of Cardiovascular Disease in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors. Blood, 2012, 120, 1573-1573.	1.4	0
221	Expression but Not Promoter Hypermethylation of the Tyrosine Phosphatase PTPN6 Is Associated with Activated STAT3 and Inferior Prognosis in Diffuse Large B Cell Lymphoma Molecular Subtypes.. Blood, 2012, 120, 2655-2655.	1.4	0
222	Prognostic Value of Six Germline Single Nucleotide Polymorphisms At the REL, HLA-DRA, GATA3 and PVT1 Loci Identified in a Classical Hodgkin Lymphoma Genome-Wide Association Study: A Meta-Analysis of 601 Patients for Progression-Free Survival From Two Independent Studies. Blood, 2012, 120, 3637-3637.	1.4	0
223	CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis.. Blood, 2012, 120, 2702-2702.	1.4	0
224	Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood, 2011, 118, 4053-4061.	1.4	136
225	Phase I and pharmacological study of cytarabine and tansespimycin in relapsed and refractory acute leukemia. Haematologica, 2011, 96, 1619-1626.	3.5	37
226	Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood, 2011, 117, 1492-1498.	1.4	110
227	Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood, 2011, 118, 4882-4889.	1.4	37
228	Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. Blood, 2011, 118, 2821-2826.	1.4	50
229	Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. American Journal of Hematology, 2011, 86, 998-1000.	4.1	28
230	Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2011, 29, 1620-1626.	1.6	70
231	Cardiac Outcomes in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors. Blood, 2011, 118, 2656-2656.	1.4	26
232	Pretreatment Serum Cytokines Predict Early Disease Relapse and A Poor Prognosis In Newly Diagnosed Classical Hodgkin Lymphoma (cHL) Patients. Blood, 2011, 118, 429-429.	1.4	1
233	Elevated Serum IL-10 Levels in Patients with Diffuse Large B Cell Lymphoma: A Mechanism of Aberrant JAK2 Kinase Activation. Blood, 2011, 118, 960-960.	1.4	0
234	Elevated Monoclonal Free Light Chains Are a Serum Marker of ABC Type Diffuse Large B-Cell Lymphoma. Blood, 2011, 118, 1591-1591.	1.4	0

#	ARTICLE	IF	CITATIONS
235	Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era. International Journal of Molecular Epidemiology and Genetics, 2011, 2, 245-52.	0.4	7
236	Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen. Cancer Immunology, Immunotherapy, 2010, 59, 161-171.	4.2	12
237	Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma. Cancer, 2010, 116, 2993-3000.	4.1	68
238	Expression of LMO2 Is Associated With t(14;18)/IGH-BCL2 Fusion but Not BCL6 Translocations in Diffuse Large B-Cell Lymphoma. American Journal of Clinical Pathology, 2010, 134, 278-281.	0.7	8
239	Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era. Journal of Clinical Oncology, 2010, 28, 412-417.	1.6	75
240	Inherited Determinants of Ovarian Cancer Survival. Clinical Cancer Research, 2010, 16, 995-1007.	7.0	56
241	Reply to J.R. Carver et al. Journal of Clinical Oncology, 2010, 28, e612-e612.	1.6	0
242	Reply to C. Barker et al and H. Asai et al. Journal of Clinical Oncology, 2010, 28, e427-e428.	1.6	0
243	A Degenerate HLA-DR Epitope Pool of HER-2/neu Reveals a Novel In vivo Immunodominant Epitope, HER-2/neu88-102. Clinical Cancer Research, 2010, 16, 825-834.	7.0	15
244	Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2010, 28, 4191-4198.	1.6	184
245	18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of "indeterminate" reports. Leukemia and Lymphoma, 2010, 51, 439-446.	1.3	21
246	Genetic Polymorphisms In Genes Involved In R-CHOP Metabolism and Event-Free and Overall Survival In Diffuse Large B-Cell Lymphoma. Blood, 2010, 116, 996-996.	1.4	2
247	Pretreatment Serum Cytokines Predict Early Disease Relapse and a Poor Prognosis In Diffuse Large B-Cell Lymphoma (DLBCL) Patients. Blood, 2010, 116, 991-991.	1.4	1
248	Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology, 2009, 27, 2052-2058.	1.6	323
249	Complementary and alternative medicine use among long-term lymphoma survivors: A pilot study. American Journal of Hematology, 2009, 84, 795-798.	4.1	49
250	PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.. Blood, 2009, 114, 137-137.	1.4	5
251	Vitamin D Deficiency Is Associated with Inferior Event-Free and Overall Survival in Diffuse Large B-Cell Lymphoma.. Blood, 2009, 114, 1952-1952.	1.4	0
252	MYC Translocations Are Associated with Poor Overall Survival in DLBCL Patients in Both the Chemotherapy and Immunochemotherapy Eras.. Blood, 2009, 114, 443-443.	1.4	0

#	ARTICLE	IF	CITATIONS
253	Germline Variation in Complement Genes and Event-Free Survival in Follicular Lymphoma.. Blood, 2009, 114, 440-440.	1.4	4
254	A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma. Cancer, 2008, 112, 1772-1779.	4.1	19
255	Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma. Cancer, 2008, 113, 508-514.	4.1	220
256	An HLA-DR*4 Degenerate Epitope Pool Detects Insulin-like Growth Factor Binding Protein 2-Specific Immunity in Patients with Cancer. Cancer Research, 2008, 68, 4893-4901.	0.9	16
257	A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma. Clinical Cancer Research, 2008, 14, 6697-6703.	7.0	149
258	Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood, 2008, 112, 2694-2702.	1.4	64
259	Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood, 2007, 109, 5439-5446.	1.4	109
260	A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).. Blood, 2007, 110, 121-121.	1.4	31
261	Host Genetic Variation in the Cell Cycle and NF- κ B Pathways and Overall Survival in Mantle Cell Lymphoma.. Blood, 2007, 110, 1582-1582.	1.4	0
262	Polymorphisms in One-Carbon Metabolism Genes and Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL).. Blood, 2007, 110, 1568-1568.	1.4	1
263	A Phase I Trial of CpG-7909, Rituximab Immunotherapy, and Y90 Zevalin Radioimmunotherapy for Patients (Pts) with Previously Treated CD20+ Non-Hodgkin Lymphoma (NHL).. Blood, 2007, 110, 124-124.	1.4	2
264	Prospective Study of Quality of Life in Adults with Newly Diagnosed High-grade Gliomas. Journal of Neuro-Oncology, 2006, 76, 283-291.	2.9	161
265	A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Cancer, 2006, 107, 2826-2832.	4.1	44
266	Validation of neuroradiologic response assessment in gliomas: Measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods1. Neuro-Oncology, 2006, 8, 156-165.	1.2	117
267	Randomized Phase II Study of Interleukin-12 in Combination with Rituximab in Previously Treated Non-Hodgkin's Lymphoma Patients. Clinical Cancer Research, 2006, 12, 6056-6063.	7.0	52
268	Germline Single Nucleotide Polymorphisms (SNPs) in IL1A, IL6, IL10, and IFNGR2 in Combination with Clinical with Demographic Factors Predict Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL).. Blood, 2006, 108, 2028-2028.	1.4	0
269	Smoking, Obesity and Overall Survival in Non-Hodgkin Lymphoma (NHL): A Population-Based Study.. Blood, 2006, 108, 4649-4649.	1.4	0
270	Cytokine Gene Polymorphisms and Overall Survival in Follicular Lymphoma: Results from a Large Population-Based Study.. Blood, 2006, 108, 820-820.	1.4	0

#	ARTICLE	IF	CITATIONS
271	Host Immunogenetic Single Nucleotide Polymorphisms (SNPs) Predict Overall Survival in Small Lymphocytic Lymphoma.. Blood, 2006, 108, 2396-2396.	1.4	0
272	A Prospective Study of Quality of Life in Adults with Newly Diagnosed High-grade Gliomas: The Impact of the Extent of Resection on Quality of Life and Survival. Neurosurgery, 2005, 57, 495-504.	1.1	186
273	Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): Results of North Central Cancer Treatment Group trial 98-72-51. International Journal of Radiation Oncology Biology Physics, 2005, 61, 380-386.	0.8	13
274	Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. Genes Chromosomes and Cancer, 2005, 42, 68-77.	2.8	89
275	Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: A North Central Cancer Treatment Group trial. Investigational New Drugs, 2005, 23, 495-503.	2.6	20
276	Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology, 2005, 23, 5294-5304.	1.6	688
277	Clinical trials in lymphoma. , 0, , 45-60.		0
278	Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients With Aggressive Lymphoma: A Prospective Cohort Analysis. JCO Oncology Practice, 0, , .	2.9	0